SCHEMBL13651779

SCHEMBL13651779

CCCOc1ccc(C2OCC2(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ MAOA P21397 3/20 0.46
▸ MAOB P27338 3/20 0.46
▸ CACNA1B Q00975 1/20 0.42
▸ APBA1 Q02410 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ LTA4H P09960 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ TSHR P16473 2/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4806456 0.94 NPC1 (0.48) ALDH1A1MAPTMAOAMAOBNPC1
SCHEMBL13651823 0.92 MAPT (0.39) ALDH1A1MAPTMAOAMAOBNPC1
SCHEMBL14193797 0.91 LMNA (0.51) ALDH1A1MAPTMAOAMAOBNPC1
SCHEMBL13651773 0.90 LMNA (0.50) MAPTMAOAMAOBNPC1LMNA
SCHEMBL13651772 0.90 LMNA (0.50) MAPTMAOAMAOBNPC1LMNA
SCHEMBL13651821 0.88 ALDH1A1 (0.36) ALDH1A1MAPTNPC1LMNATSHR
SCHEMBL13651775 0.87 CRBN (0.44) ALDH1A1MAPTMAOAMAOBNPC1
SCHEMBL13183274 0.87 NQO1 (0.47) ALDH1A1MAPTMAOAMAOBLMNA
SCHEMBL4807583 0.87 EPHX2 (0.39) ALDH1A1MAPTMAOAMAOBNPC1
SCHEMBL4809265 0.86 MAPT (0.35) ALDH1A1MAPTMAOAMAOBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090252895-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-10-08 — — US disclosed
US-20090252895-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-10-08 — — US disclosed
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-05-08 — — US disclosed
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-05-08 — — US disclosed
EP-1840148-A1 POLYMERIZABLE ACTINIC RADIATION CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTINIC RADIATION CURABLE INK AND IMAGE FORMATION METHOD, AND INK JET RECORDING APPARATUS AND EPOXY COMPOUND Konica Minolta Medical & Graphic, Inc. (JP) 2007-10-03 — — EP disclosed
US-20070219292-A1 INK SET FOR INK-JET RECORDING, POLYMERIZATION METHOD AND IMAGE FORMING METHOD KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-09-20 — — US disclosed
US-20070219292-A1 INK SET FOR INK-JET RECORDING, POLYMERIZATION METHOD AND IMAGE FORMING METHOD KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-09-20 — — US disclosed
EP-1829936-A1 ACTIVE RAY-CURABLE COMPOSITION, ACTIVE RAY-CURABLE INK AND IMAGE-FORMING METHOD Konica Minolta Medical & Graphic, Inc. (JP) 2007-09-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound CBR3, CBR1, CNR1 ALDH1A1 3110/4885MAPT 3075/4885MAOA 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback